Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer

Stoll, Joseph R.; Vaidya, Toral; Mori, Shoko; Dusza, Stephen W.; Lacouture, Mario E.; Markova, Alina

doi:10.1016/j.jaad.2020.03.010

Cited by 14 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High cytokine levels can also be induced by chemo- and radiotherapy [123] . In a recent study it was shown that hospitalized non-COVID-19 cancer patients with a rash secondary to cytostatic or targeted treatment and elevated IL-6 and TNF-α were nearly 6 times more likely to die over the course of follow-up [124] . Upregulation of inflammatory cytokines is not unique for cancer patients and is also seen in patients with diabetes, cardiovascular disease, autoimmune disorders, obesity and other diseases [125] , [126] .…”

Section: Potential Biomarkers To Identify High Risk Patients and Targmentioning

confidence: 99%

SARS-CoV-2 and cancer: Are they really partners in crime?

Dam

Huizing

Mestach

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

Highlights Cancer patients with COVID-19 have a higher morbidity and mortality. Particularly patients with ongoing or recent cancer treatment, metastatic solid tumors and hematological malignancies are at risk. Underlying immunosuppression, elevated cytokine levels, altered expression of the angiotensin converting enzyme (ACE-2) and TMPRSS2, and a prothrombotic status in cancer patients may fuel the effects of a SARS-CoV-2 sepsis. The gene expression level of ACE2 may be an indicator of the susceptibility to SARS-CoV-2 infection, while TMPRSS2 plays a supporting role. Better knowledge of the mechanisms involved may be a tool to identify high risk patients and to prevent severe complications by targeting the involved pathways.

show abstract

Section: Potential Biomarkers To Identify High Risk Patients and Targmentioning

confidence: 99%

SARS-CoV-2 and cancer: Are they really partners in crime?

Dam

Huizing

Mestach

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…Comorbidities such as diabetes and cancer can affect baseline IL-6 level [19,20]; we therefore used logistic regression models to adjust for the effect of potential confounders. However, the signi cant association between baseline IL-6 level andrisk of severe illnesspersisted even after adjustment for all potential confounders (Models1-3; Table 2).…”

Section: Discussionmentioning

confidence: 99%

Baseline Interleukin-6 Level Predicts Risk of Severe COVID-19: A Two-Center, Retrospective Study

Zhu

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background:The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has affected almost every country. Interleukin-6 (IL-6), a cytokine secreted by CD4+ T cell, has been shown to be a reliable marker of disease severity and a useful parameter for monitoring progression of coronavirus disease-2019 (COVID-19). However its value as a predictor of severe disease has not been assessed.Methods:A total of 160 laboratory-confirmed COVID-19 patients admitted to two hospitals were enrolledand separated into two groups according to whether or not they progressed to develop severe illness. Demographic and clinical characteristics at admission were compared between the groups.Results: Patients who developed severe COVID-19 had significantly higher baseline IL-6 levels than patients who had mild disease course in hospital (P< 0.001). Patients were further grouped according to quartiles of IL-6 level. The cumulative incidence of severe illnesswas significantly higher in the third and fourth quartiles groups than in the first quartile group (55% vs. 15% and 80% vs. 15%, respectively;bothP< 0.001). In multivariate logistic regression analysis, the risk for developing severe disease was markedly higher in the highest IL-6 quartile than in the lowest quartile (odds ratio: 14.95; 95% confidence interval: 3.65–61.30; P< 0.001). Receiver operating characteristic curve analysis of potential predictive variables showed the area under the curve to be largest for baseline IL-6, with the value of 5.20 pg/mL having the best balance of sensitivity and specificity for predicting risk of severe COVID-19.Conclusion: Serum baseline IL-6 appears to be a reliable predictor of risk of severe COVID-19. Early intervention may be advisable in patients with serum IL-6 levels >5.20 pg/mL, even if initial symptoms are mild.

show abstract

“…In recent decades, TNFα levels in serum have been demonstrated to be significantly associated with the activity and progression of disease and cancer, such as periodontal disease, ankylosing spondylitis, skin cancer, hematological tumor, etc [23][24][25]. In breast cancer patients, elevated levels of TNFα can be detected both in blood serum and in the tumor tissue [26].…”

Section: Serum Concentration Of Tnfα In Breast Cancer Patientsmentioning

confidence: 99%

An Overview of Tumor Necrosis Factor-α on Pathophysiological Mechanisms, Relevant Therapeutic Status in Breast Cancer

Li¹

2022

HSET

View full text Add to dashboard Cite

TNFα is an essential pro-inflammatory cytokine that is prevalent in the tumor microenvironment and is involved in mediating or activating many significant signaling pathways which result in inflammation, apoptosis, and tumor cell proliferation, survival, and invasiveness. In breast cancer, TNFα is involved throughout all stages from occurrence, development, procession, and metastasis to recurrence. Researchers have pointed out that TNFα plays a major role in the estrogen biosynthesis pathway, especially in the process of adipose tissue switching to estrogen. In the breast tumor microenvironment, TNFα may participate in the mediation of estrone sulfatase expression and activity. In terms of therapeutics, methods to suppress TNFα signaling in breast cancer have been proposed. To neutralize the pro-tumor and inflammatory effects of TNFα, most research opts to use anti-TNFα antibodies. According to the research, the administration of TNFα antagonists can suppress the development of breast cancer cells and strengthen the chemotherapeutic response when used as adjuvant therapy with chemotherapy. Consequently, tumor drug resistance can be well controlled. However, some side effects like systemic toxicity, the typical skin lesion, and the increasing risk of developing new cancers are still major issues. More extensive clinical trials have to be carried out for deeper investigation. This paper gives an overview of the intrinsic features of TNFα as a cytokine and gets insight into the pathophysiological mechanisms mediated by TNFα in breast cancer. Furthermore, the current state of knowledge in terms of TNF-related therapeutic strategies was adequately summarized and discussed.

show abstract

Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer

Cited by 14 publications

References 51 publications

SARS-CoV-2 and cancer: Are they really partners in crime?

SARS-CoV-2 and cancer: Are they really partners in crime?

Baseline Interleukin-6 Level Predicts Risk of Severe COVID-19: A Two-Center, Retrospective Study

An Overview of Tumor Necrosis Factor-α on Pathophysiological Mechanisms, Relevant Therapeutic Status in Breast Cancer

Contact Info

Product

Resources

About